Design Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DSGN | SLDB | MGTX | STOK | RGNX | SRPT | |
|---|---|---|---|---|---|---|
| Market cap | 665.24M | 699.11M | 904.72M | 1.78B | 508.96M | 2.01B |
| P/E (TTM) | — | — | 10.8 | — | — | — |
| Forward P/E | -6.6 | -3.8 | -6.2 | -7.3 | -2.6 | 7.8 |
| Price/book | 3.0 | 2.9 | 4.1 | 5.0 | 5.8 | 1.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +54.73% | +54.69% | +12.01% | +22.16% | −30.98% | +7.65% |
| Today | +2.80% | +3.82% | −1.05% | +1.70% | +1.05% | +2.43% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All DSGN news ›Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
--Design Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2026 financial results and highlighted business updates and upcoming…
Design Therapeutics GAAP EPS of -$0.32 beats by $0.02
Design Therapeutics Q3 results: GAAP EPS of -$0.32 beat estimates by $0.02. - Design Therapeutics press release (DSGN): Q3 GAAP EPS of -$0.32 beats by $0.02. - Cash Position: Cash, cash equivalents and investment securities were $208.6…
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results
Posted by Tristan Rich on Nov 5th, 2026 Design Therapeutics (NASDAQ:DSGN – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus…
Design Therapeutics (DSGN) Expected to Release Earnings on Wednesday
Posted by Mitch Edgeman on Oct 28th, 2026 Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, beating…
Friedreich's Ataxia Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Minoryx Therapeutics, Takeda, Reata Pharma, Design Therapeutics
Albany New York October 15 2026 As per DelveInsight s assessment globally Friedreich s Ataxia pipeline constitutes 18 key companies continuously working towards developing 20 Friedreich s Ataxia treatment therapies analysis of Clinical…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- seekingalpha.com2
- manilatimes.net1
- openpr.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.